Antianemic therapy as an important component of treatment of uterine leiomyoma

Authors

  • Т. Ф Татарчук Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine, Ukraine
  • Н. В. Косей Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine, Ukraine
  • Н. А. Редько Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2013.14.7-16

Keywords:

uterine leiomyoma, iron defi ciency anemia, embolization of uterine vessels, iron hydroxide polymaltose complex

Abstract

Anemia correction in the treatment of symptomatic uterine leiomyoma is an important step that signifi cantly improves the quality of life of women with this
pathology, thereby increasing the effi ciency of organ surgery, reducing the risk of complications.
Anemia treatment in the preoperative period contributes to a more favorable course of the postoperative period after embolization of uterine vessels, reduces the
severity and duration of the postembolization syndrome, accelerates the timing of rehabilitation, reduces the risk of infl ammatory complications.
When you selecting drugs for the treatment of iron defi ciency anemia should be preferred non-ionic iron drugssuch as the iron hydroxide polymaltose complex as the most safe and highly eff ective.

Author Biographies

Т. Ф Татарчук, Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine

MD, professor, corresponding member of NAMS of Ukraine, Deputy Director for Research Work, Chief of the
Endocrine Gynecology Department

Н. В. Косей, Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine

MD, Chief researcher at the Department of Endocrine Gynecology

References

  1. Аrutyunyan AF Thesis abstract on a Ph.D. St. Petersburg. 2002, 23 p.
  2. Budanov PV, Aslanov AG Therapy problems of the manifest iron defi ciencyinobstetricsandgynecology. Diffi cultPatient. № 8–9–2011.
  3. Burlev VA, Konovodova EN Modern possibilities of path ogenetictreatmentofi rondefi ciencyanemiainpatientswith uterinemyoma. Reproduction Problems. – 2003. – № 5. – C. 23-27.
  4. Burlev VA, Gasparov AS et al. Epocryn in the treatment of iron defi ciency anemia in patients with uterine myoma after hysterectomy. Reproduction Problems. 2003, 6: 59–64.
  5. Vihljaeva EM Guidelines for the diagnosis and treatment of uterine leiomyoma. M: MED press Inform, 2004.
  6. Davydov AI Rehabilitation treatment after organ-serving surgery in patients with submucosal uterine leiomyoma and adenomyosis. Gynecology, ObstetricsandPerinatologyIssues. – № 6, 2011. – P. 13–21.
  7. Dvoretsky LI, Zaspa EA, Litvitskiy PF, Bolevich SB, Menshova NI Free radical processes in patients with iron defi ciency anemia during treatment with iron // Therapeutic Archives, 2006, 78 (1): p. 52–57.
  8. Idelson LN Hypochromic anemia. M., 1980.
  9. Kistenev BA, Maximova AV, Lagutin AV Ischemic stroke in patient suff ering from iron defi ciency anemia.Atmosphere. Nervous Diseases. 2007, № 2, p. 27–31.
  10. Konovodova EN, Dokuyeva RS-E, Yakunina NA Iron defi ciency in obstetric practice. RMJ, 2011, 20: 1228–1231.
  11. Konovodova EN, Burlev VA Symptomatic treatment of iron defi ciency in gynecological patients in the pre-and postoperative period. Reproduction Problems.2003, 5: 23–7.
  12. Lebedev VA, Pashkov VM Pathogenesis and treatment of iron defi ciency anemia in pregnancy. Diffi cult Patient. 2011, 9, 2–3: 8–12.
  13. Maltofer. Monograph on the drug. – 3rd ed. – Moscow: Mega Pro 2001.
  14. Pavlov AD Pathological. Physiology and Experimental.Therapy.1991. Number 4.P. 57.
  15. Palamarchuck OA, Parashchuk VY Uterine leiomyoma: Method. decree For students and medical interns – Kharkiv: KhNMU 2012. – 20 p.
  16. Vorobyov AI Hematology Guidelines. Moscow, 2005.
  17. Sawicki GA, Sawicki AG Uterine Fibroids: problems of pathogenesis and pathogenetic therapy. St. Petersburg. 2000.
  18. Serov VN, Dubrovin NV, Balushkina AA Iron defi ciency anemia in gynecological practice : the basic principles of treatment of Resolution (series AA number 0000151) of the Federal Service on Surveillance in Healthcare and Social Development of the use of new medical technology FS number 2010/003 dated 18.01.2010, M.: MedExpertPress 2010. – 28 p.
  19. Strizhakov AN, Davydov AI et al. Benign uterine diseases. Moscow, GEOTAR Media, 2011, 288.
  20. Tarasova IS, Chernov VM Factors determining the correctness and eff ectiveness of the treatment of children with iron defi ciency anemia.Questions of the Practical Pediatrics, 2011, Vol. 6, № 3, p. 1 5.
  21. Tikhomirov AL, Sarsaniya SI, Nochevkin EV Iron defi ciency in obstetrics and gynecology.Facets of the problem.Moderntreatment. Farmateka.http://www.rmj.ru/articles_7485.htm.
  22. Hamko VA, Ukybasova TM Mechanismofbleedingatuterinefi broids. // St.Petersburg: «ClinicalMedicine» – Novgorod-Almaty, Vol. 6, 2000. – P.84–89.
  23. Hamko VA Disorders of the hormone synthesis as the cause of bleeding in uterine fi broids. // Modern problems of theoretical and clinical medicine. Digest of the III International Conference of young medical scientists of CIS. Almaty, 2001. – P. 223–224.
  24. Yaglov VV Iron defi ciency in patients with uterine bleeding.
  25. Abnormal Uterine Bleeding and Uterine Fibroids: Medical Policy (Eff ective 10/01/2012) UnitedHealthcarePolicy Number: 2012T0442H.
  26. Andrew F Goddard,1 Martin W James,2 Alistair S McIntyre, 3 Brian B Scott 4 on behalf of the British Society of Gastroenterology Guidelines for the management of iron defi ciency anaemia Gut 2011;60:1309e1316. doi:10.1136/gut.2010.228874.
  27. Horne M.C. // Consultative Hemostasis and Thrombosis. Philadelphia, 2002.P. 15.
  28. Johnson-Wimbley T.D., Graham D.Y. Diagnosis and management of iron defi ciency anemia in the 21st century. Therap. Adv. Gastroenterol. 2011; 4 (3): 177–84.
  29. Iron defi ciency anemia assessment, prevention and control. A guid for programme managers – Geneva: World Health Organization, 2001 (WHO/NHD/01.3).
  30. Kraaijtnhagen RA et al. // Thromb. Haemost. 2000. V. 83. P. 5.
  31. Koster T et al. // Lancet. 1995. V. 345. P. 152.
  32. Nirmala Jaget Lakkawar, Santoshi Sankaran, ThirupurasundariRangaswamyEffi cacy of Intravenous Administration of Iron Sucrose for Treatment of Iron Defi ciency Anaemia in Patients With Abnormal Uterine Bleeding; Scientifi c Journal of the Faculty of Medicine in Niš 2012;29(2):59–68.
  33. O’Donnell J et al. // Thromb. Haemost. 2000. V. 83. P. 10.
  34. Ortiz et al., 2011 (Colombia/Argentina)Erratum: J Matern Fetal Neonatal Med 2011;24:1347–52.
  35. Pasricha SR, Flecknoe-Brown SC, Allen KJ et al. Diagnosis and management of iron defi ciency anaemia: a clinical update. Med. J. Aust. 2010; 193 (9): 525–32.
  36. Peter Jacobsa, Lucille Wood’and ARTHUR RBIRDb Better Tolerance of Iron Polymaltose Complex Compared with Ferrous Sulphate in the Treatment of Anaemia Hematology, 2000, Vol. 5, pp. 77–83
  37. Rosendaal FR // Thromb. Haemost. 2000. V. 83. P. 1.
  38. Source: www.eff ectivehealthcare.ahrq.gov Published Online: November 21, 2011.
  39. Toblli JE, Cao G, Olivieri L, Angerosa M Comparative study of gastrointestinal tract and liver toxicity of ferrous sulfate, iron amino chelate and iron polymaltose complex in normal rats. Pharmacology. 2008;82(2):127–37. Epub 2008 Jul 8.
  40. UNICEF/UNU/WHO. Iron Defi ciency Anemia: Assessment, Prevention, and Control. A Guide for Programme Managers. Geneva: WHO/NHD, 2001.

Published

2013-11-12

How to Cite

Татарчук, Т. Ф., Косей, Н. В., & Редько, Н. А. (2013). Antianemic therapy as an important component of treatment of uterine leiomyoma. REPRODUCTIVE ENDOCRINOLOGY, (14), 7–16. https://doi.org/10.18370/2309-4117.2013.14.7-16

Issue

Section

Analytical review

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 > >>